Inhibition of olfactory neurosensory function to treat eating disorders and obesity
AssigneeCompellis Pharmaceuticals
InventorsChristopher P. Adams, James Flynn
Life of this patent
Estimating the term…
Abstract
The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical composition comprising an effective amount of a calcium channel blocker to the nasal mucosa, as well as screening methods for drugs to be used in treating obesity or associated disorders.
Claims22
A method of reducing food intake of a subject, comprising intranasal administration of a pharmaceutical composition comprising an effective amount of a calcium channel blocker to a subject in need of such treatment.
A method of treating or preventing obesity, comprising intranasal administration of a pharmaceutical composition comprising an effective amount of diltiazem to a subject suffering from or at risk for obesity.
A method of screening to identify an agent useful for treating or preventing obesity which comprises
- (i) providing a pool of test agents;
- (ii) determining whether any test agent from the pool is an antagonist of a cyclic-nucleotide-gated calcium channel specific for olfactory neurons;
- (iii) selecting any test agent from the pool that is an antagonist as an agent useful for treating or preventing obesity.
Dependencies are inferred from the claim text.